MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.9521
+0.0043
+0.45%
Opening 12:17 06/29 EDT
OPEN
0.9573
PREV CLOSE
0.9478
HIGH
0.9700
LOW
0.9461
VOLUME
488.10K
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.5614
MARKET CAP
110.57M
P/E (TTM)
-2.9874
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ONCY last week (0622-0626)?
Weekly Report · 6h ago
Weekly Report: what happened at ONCY last week (0615-0619)?
Weekly Report · 06/22 10:26
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS)
TipRanks · 06/18 13:40
Oncolytics' New U.S Patent Extends Pelareorep Manufacturing Protection Into 2044
NASDAQ · 06/17 07:48
Oncolytics secures new patent for pelareorep manufacturing
TipRanks · 06/16 13:38
Oncolytics Biotech Receives New U.S. Patent For Its Proprietary Manufacturing Process For Pelareorep
Benzinga · 06/16 13:02
Oncolytics Biotech wins new US manufacturing patent for pelareorep, protection through 2044
PUBT · 06/16 13:01
ONCOLYTICS BIOTECH - NEW PATENT PROVIDES PELAREOREP MANUFACTURING PROTECTION INTO 2044
Reuters · 06/16 13:00
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.